276 related articles for article (PubMed ID: 28899102)
1. Community Based Antiretroviral Treatment in Rural Zimbabwe.
Chimukangara B; Manasa J; Mitchell R; Nyabadza G; Katzenstein D; Masimirembwa C
AIDS Res Hum Retroviruses; 2017 Dec; 33(12):1185-1191. PubMed ID: 28899102
[TBL] [Abstract][Full Text] [Related]
2. Clinical, Virologic, Immunologic Outcomes and Emerging HIV Drug Resistance Patterns in Children and Adolescents in Public ART Care in Zimbabwe.
Makadzange AT; Higgins-Biddle M; Chimukangara B; Birri R; Gordon M; Mahlanza T; McHugh G; van Dijk JH; Bwakura-Dangarembizi M; Ndung'u T; Masimirembwa C; Phelps B; Amzel A; Ojikutu BO; Walker BD; Ndhlovu CE
PLoS One; 2015; 10(12):e0144057. PubMed ID: 26658814
[TBL] [Abstract][Full Text] [Related]
3. Nevirapine- versus lopinavir/ritonavir-based initial therapy for HIV-1 infection among women in Africa: a randomized trial.
Lockman S; Hughes M; Sawe F; Zheng Y; McIntyre J; Chipato T; Asmelash A; Rassool M; Kimaiyo S; Shaffer D; Hosseinipour M; Mohapi L; Ssali F; Chibowa M; Amod F; Halvas E; Hogg E; Alston-Smith B; Smith L; Schooley R; Mellors J; Currier J;
PLoS Med; 2012; 9(6):e1001236. PubMed ID: 22719231
[TBL] [Abstract][Full Text] [Related]
4. Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis.
Boyd MA; Moore CL; Molina JM; Wood R; Madero JS; Wolff M; Ruxrungtham K; Losso M; Renjifo B; Teppler H; Kelleher AD; Amin J; Emery S; Cooper DA;
Lancet HIV; 2015 Feb; 2(2):e42-51. PubMed ID: 26424460
[TBL] [Abstract][Full Text] [Related]
5. Low Incidence of HIV-1C Acquired Drug Resistance 10 Years after Roll-Out of Antiretroviral Therapy in Ethiopia: A Prospective Cohort Study.
Mulu A; Maier M; Liebert UG
PLoS One; 2015; 10(10):e0141318. PubMed ID: 26512902
[TBL] [Abstract][Full Text] [Related]
6. Nevirapine- Versus Lopinavir/Ritonavir-Based Antiretroviral Therapy in HIV-Infected Infants and Young Children: Long-term Follow-up of the IMPAACT P1060 Randomized Trial.
Barlow-Mosha L; Angelidou K; Lindsey J; Archary M; Cotton M; Dittmer S; Fairlie L; Kabugho E; Kamthunzi P; Kinikar A; Mbengeranwa T; Msuya L; Sambo P; Patel K; Barr E; Jean-Phillipe P; Violari A; Mofenson L; Palumbo P; Chi BH
Clin Infect Dis; 2016 Oct; 63(8):1113-1121. PubMed ID: 27439527
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of nonsuppressed viral load and associated factors among HIV-positive adults receiving antiretroviral therapy in Eswatini, Lesotho, Malawi, Zambia and Zimbabwe (2015 to 2017): results from population-based nationally representative surveys.
Haas AD; Radin E; Hakim AJ; Jahn A; Philip NM; Jonnalagadda S; Saito S; Low A; Patel H; Schwitters AM; Rogers JH; Frederix K; Kim E; Bello G; Williams DB; Parekh B; Sachathep K; Barradas DT; Kalua T; Birhanu S; Musuka G; Mugurungi O; Tippett Barr BA; Sleeman K; Mulenga LB; Thin K; Ao TT; Brown K; Voetsch AC; Justman JE
J Int AIDS Soc; 2020 Nov; 23(11):e25631. PubMed ID: 33225559
[TBL] [Abstract][Full Text] [Related]
8. Accumulation of HIV-1 drug resistance after continued virological failure on first-line ART in adults and children in sub-Saharan Africa.
Boender TS; Kityo CM; Boerma RS; Hamers RL; Ondoa P; Wellington M; Siwale M; Nankya I; Kaudha E; Akanmu AS; Botes ME; Steegen K; Calis JC; Rinke de Wit TF; Sigaloff KC
J Antimicrob Chemother; 2016 Oct; 71(10):2918-27. PubMed ID: 27342546
[TBL] [Abstract][Full Text] [Related]
9. Second-line antiretroviral therapy failure and characterization of HIV-1 drug resistance patterns in children in Mali.
Sylla M; Dolo O; Maiga AI; Traore FT; Coulibaly YA; Togo J; Fofana DB; Dicko-Traore F; Doumbia S; Orsega S; Diallo S; Murphy RL; Calvez V; Marcelin AG
Arch Pediatr; 2019 Jul; 26(5):254-258. PubMed ID: 31307909
[TBL] [Abstract][Full Text] [Related]
10. Virologic failure among children taking lopinavir/ritonavir-containing first-line antiretroviral therapy in South Africa.
Meyers T; Sawry S; Wong JY; Moultrie H; Pinillos F; Fairlie L; van Zyl G
Pediatr Infect Dis J; 2015 Feb; 34(2):175-9. PubMed ID: 25741970
[TBL] [Abstract][Full Text] [Related]
11. Rapid development of antiretroviral drug resistance mutations in HIV-infected children less than two years of age initiating protease inhibitor-based therapy in South Africa.
Taylor BS; Hunt G; Abrams EJ; Coovadia A; Meyers T; Sherman G; Strehlau R; Morris L; Kuhn L
AIDS Res Hum Retroviruses; 2011 Sep; 27(9):945-56. PubMed ID: 21345162
[TBL] [Abstract][Full Text] [Related]
12. HIV-1 second-line failure and drug resistance at high-level and low-level viremia in Western Kenya.
Kantor R; DeLong A; Schreier L; Reitsma M; Kemboi E; Orido M; Obonge S; Boinett R; Rono M; Emonyi W; Brooks K; Coetzer M; Buziba N; Hogan J; Diero L
AIDS; 2018 Nov; 32(17):2485-2496. PubMed ID: 30134290
[TBL] [Abstract][Full Text] [Related]
13. High level of HIV-1 drug resistance mutations in patients with unsuppressed viral loads in rural northern South Africa.
Etta EM; Mavhandu L; Manhaeve C; McGonigle K; Jackson P; Rekosh D; Hammarskjold ML; Bessong PO; Tebit DM
AIDS Res Ther; 2017 Jul; 14(1):36. PubMed ID: 28750647
[TBL] [Abstract][Full Text] [Related]
14. Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy.
Svärd J; Mugusi S; Mloka D; Neogi U; Meini G; Mugusi F; Incardona F; Zazzi M; Sönnerborg A
PLoS One; 2017; 12(6):e0178942. PubMed ID: 28582463
[TBL] [Abstract][Full Text] [Related]
15. Predictors of virologic and clinical response to nevirapine versus lopinavir/ritonavir-based antiretroviral therapy in young children with and without prior nevirapine exposure for the prevention of mother-to-child HIV transmission.
Lindsey JC; Hughes MD; Violari A; Eshleman SH; Abrams EJ; Bwakura-Dangarembizi M; Barlow-Mosha L; Kamthunzi P; Sambo PM; Cotton MF; Moultrie H; Khadse S; Schimana W; Bobat R; Zimmer B; Petzold E; Mofenson LM; Jean-Philippe P; Palumbo P;
Pediatr Infect Dis J; 2014 Aug; 33(8):846-54. PubMed ID: 25222305
[TBL] [Abstract][Full Text] [Related]
16. [Analysis of HIV genotypic drug resistance among pediatric HIV/AIDS cases with virological failure after free antiretroviral therapy in Yunnan province].
Zhong M; Yang S; Yang B; Liu J; Li J; Lou J; Li H
Zhonghua Yi Xue Za Zhi; 2014 Apr; 94(12):884-8. PubMed ID: 24854905
[TBL] [Abstract][Full Text] [Related]
17. Antiretroviral drug resistance profiles and response to second-line therapy among HIV type 1-infected Ugandan children.
Musiime V; Kaudha E; Kayiwa J; Mirembe G; Odera M; Kizito H; Nankya I; Ssali F; Kityo C; Colebunders R; Mugyenyi P
AIDS Res Hum Retroviruses; 2013 Mar; 29(3):449-55. PubMed ID: 23308370
[TBL] [Abstract][Full Text] [Related]
18. Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the Western Cape, South Africa.
van Zyl GU; van der Merwe L; Claassen M; Zeier M; Preiser W
J Med Virol; 2011 Oct; 83(10):1764-9. PubMed ID: 21837793
[TBL] [Abstract][Full Text] [Related]
19. Viral load care of HIV-1 infected children and adolescents: A longitudinal study in rural Zimbabwe.
Mapangisana T; Machekano R; Kouamou V; Maposhere C; McCarty K; Mudzana M; Munyati S; Mutsvangwa J; Manasa J; Shamu T; Bogoshi M; Israelski D; Katzenstein D
PLoS One; 2021; 16(1):e0245085. PubMed ID: 33444325
[TBL] [Abstract][Full Text] [Related]
20. Association between detection of HIV-1 DNA resistance mutations by a sensitive assay at initiation of antiretroviral therapy and virologic failure.
Jourdain G; Wagner TA; Ngo-Giang-Huong N; Sirirungsi W; Klinbuayaem V; Fregonese F; Nantasen I; Techapornroong M; Halue G; Nilmanat A; Wittayapraparat P; Chalermpolprapa V; Pathipvanich P; Yuthavisuthi P; Frenkel LM; Lallemant M;
Clin Infect Dis; 2010 May; 50(10):1397-404. PubMed ID: 20377404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
